3.32

2.35% -0.08

After Hours: 3.30 -0.02 -0.60%

Incannex Healthcare Inc (IXHL)

Overview News Price History Why IXHL Down? Discussions Forecast

Incannex Healthcare Inc stock is traded at $3.32, with a volume of 144.74K. It is down -2.35% in the last 24 hours and down -11.47% over the past month. Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Previous Close:

$3.40

Open:

$3.38

24h Volume:

144.74K

Relative Volume:

1.06

Market Cap:

$39.72M

Revenue:

$12,000

Net Income/Loss:

$-48.41M

P/E Ratio:

-0.1932

EPS:

-17.181

Net Cash Flow:

$-19.99M

1W Performance:

-8.79%

1M Performance:

-11.47%

6M Performance:

+3.11%

1Y Performance:

-81.40%

1-Day Range:

$3.26

$3.38

1-Week Range:

$3.26

$3.72

52-Week Range:

$2.49

$19.71

Incannex Healthcare Inc Stock (IXHL) Company Profile

Name

Incannex Healthcare Inc

Sector

Healthcare (1067)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

61 409 840 786

Address

8 CENTURY CIRCUIT, NORWEST NSW

Employee

Twitter

Next Earnings Date

2026-10-05

Latest SEC Filings

IXHL's Discussions on Twitter

Compare IXHL vs TAK, TEVA, HLN, ZTS, VTRS

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IXHL Incannex Healthcare Inc	3.32	39.72M	12,000	-48.41M	-19.99M	-17.18
TAK Takeda Pharmaceutical Co Adr	18.86	60.23B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	39.19	45.71B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.26	40.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	71.05	29.36B	9.51B	2.64B	2.14B	6.0361
VTRS Viatris Inc	17.83	20.48B	14.57B	-296.50M	1.64B	-0.259

Incannex Healthcare Inc Stock (IXHL) Latest News

Sep 25, 2026

Incannex Healthcare | 10-K: Annual report - Moomoo

Sep 25, 2026

Incannex Healthcare Inc. FY 2026: Revenue $0 Net income ($19.3M), EPS ($1.66) — 10-K Summary - TradingView

Sep 25, 2026

Incannex Healthcare Inc expected to post a loss of 75 cents a shareEarnings Preview - TradingView

Sep 25, 2026

Sep 10, 2026

Why Did Incannex (NASDAQ:IXHL) Dose Its First Sleep-Apnea Patient? - Kalkine Media

Sep 10, 2026

Sep 09, 2026

Incannex begins Phase 2 dosing study for sleep apnea drug By Investing.com - Investing.com South Africa

Sep 09, 2026

A company with about $70 million in cash and no debt is testing a sleep-apnea treatment. - Stock Titan

Sep 09, 2026

Sep 08, 2026

IXHLIncannex Healthcare Inc Revenue Breakdown - Finviz

Sep 08, 2026

BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Sep 08, 2026

Sep 05, 2026

Why Did IXHL Stock Tank Over 32% Today? - Stocktwits

Sep 05, 2026

Enterprise value to EBIT forward of Incannex Healthcare Limited – LSX:A2DF4D - TradingView

Sep 05, 2026

IXHL Should I Buy - intellectia.ai

Sep 05, 2026

Sep 01, 2026

IXHL Q4'26 Earnings: EPS estimate is (0.14) USD - TradingView

Sep 01, 2026

Aug 31, 2026

Incannex Healthcare (IXHL) Slides 4.97% to $3.46, Testing Support at $3.29ETF Premium Discount - vinanet.vn

Aug 31, 2026

Aug 27, 2026

What’s Next for Incannex Healthcare (ASX:IHL) After US Patent Win? - Kalkine Media

Aug 27, 2026

Aug 26, 2026

IXHL Q4'26 Earnings: revenue estimate is 0 USD - TradingView

Aug 26, 2026

Aug 25, 2026

Incannex doses first patient in sleep apnea drug trial By Investing.com - Investing.com Nigeria

Aug 25, 2026

Incannex doses first patient in sleep apnea drug trial - Investing.com India

Aug 25, 2026

Incannex (IXHL) Advances Sleep Apnea Drug Trial Amid High Price-to-Sales Valuation - GuruFocus

Aug 25, 2026

Incannex Healthcare Doses First Patient in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea - Quiver Quantitative

Aug 25, 2026

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X - Barchart.com

Aug 25, 2026

Aug 20, 2026

IXHL Stock Rips To Best Day In 5 Months: Nasdaq Compliance Back In Sight As FDA Catalyst For Sleep Apnea Drug Looms - Stocktwits

Aug 20, 2026

Aug 19, 2026

Incannex Healthcare (ASX:IHL) Cash Flow Check: What Investors Need to Watch on 19 August - Kalkine Media

Aug 19, 2026

Aug 18, 2026

Why Is Incannex Healthcare (ASX:IHL) in Market Focus? - Kalkine Media

Aug 18, 2026

Aug 17, 2026

Incannex Wins US Patent Lift For Sleep Apnoea Pipeline (ASX:IHL) - Kalkine Media

Aug 17, 2026

Aug 15, 2026

Incannex Healthcare (IXHL) Shows Modest Uptick, Holding Key Support Amid Clinical Pipeline FocusTrend Continuation Trade - vinanet.vn

Aug 15, 2026

Incannex Healthcare (IXHL) Climbs 3.8% to $3.28, Testing Key Resistance ZoneMcClellan Summation - vinanet.vn

Aug 15, 2026

Aug 14, 2026

Polar Asset Management (IXHL) reports 7.0% beneficial stake via 900,000 warrants - Stock Titan

Aug 14, 2026

Incannex (ASX:IHL): What Is Changing in the Liquidity Test? - Kalkine Media

Aug 14, 2026

Aug 13, 2026

Why Does Incannex Healthcare (ASX:IHL) Shape Discipline? - Kalkine Media

Aug 13, 2026

Incannex Healthcare (ASX:IHL) Clinical Development Pipeline: Market Outlook - Kalkine Media

Aug 13, 2026

Aug 12, 2026